CLOs on the Move

ILiAD Biotechnologies

www.iliadbio.com

 
ILiAD Biotechnologies, LLC manufactures vaccines for the prevention and treatment of disease caused by Bordetella Pertussis.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.iliadbio.com
  • 230 East 15th Street Suite 1-A
    New York, NY USA 10003
  • Phone: 954.336.0777

Executives

Name Title Contact Details

Similar Companies

Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals is a Warrendale, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Octapharma Plasma

Octapharma Plasma is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scripps Translational Science Institute

The Scripps Translational Science Institute (STSI) at The Scripps Research Institute (TSRI) aims to replace the status-quo of one-size-fits-all-medicine with individualized health care that is based on the known genetic factors influencing health and disease and that takes advantage of advances in digital technology for real-time health monitoring.

Lumen Bioscience

Lumen Bioscience develops oral antibody therapeutics.

CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead programs in beta-thalassemia and sickle cell disease have advanced to IND/CTA-enabling studies with a CTA filing planned by the end of 2017, and we are advancing additional programs in ex vivo and in vivo disease areas. In addition to our fully-owned programs, our strategic collaborations with Bayer AG and Vertex Pharmaceuticals expand our portfolio and enable us with unique capabilities. Through our private financings, partnerships, and IPO we have raised >$400M to fund and accelerate our portfolio. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. Our company is headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.